Frontlight ResearchEarly access
CompletedPhase 3
Noradrenaline plus placebo vs noradrenaline plus terlipressin for the treatment of septic shock
Key facts
- Who runs it
- Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
- Where
- Spain10 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 152 people enrolled
- Started
- 26 Jun 2024
- Ended
- 28 Dec 2024
- Type of study
- Interventional
- Record updated
- 29 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adult patients (18 years or older)
- Patients with septic shock
- Patients with a SOFA index> 4 points. (If the patient is going to be intubated at the time of randomization, take the neurological SOFA score from the medical record)
- Signature of the informed consent by the patient or his or her legal representative. (Informed consent may be granted by phone if the legal representative is not present at the center at the time of signing, with written re-consent required as soon as possible)
Who cannot take part
- Previous use of terlipressin during your stay in the ICU
- Previous use of vasopressin
- Known allergy to terlipressin
- Pathologies on which terlipressin is clinically indicated: gastrointestinal bleeding due to esophageal-gastric varices, hepatorenal syndrome
- Patients diagnosed with unstable acute coronary syndrome
- Patients with Raynaud's Phenomenon, or vasospastic disease
- Patients with active bleeding
- Pregnant or lactating patients
- Patients with acute or chronic mesenteric ischemia
- Patients participating in another intervention clinical trial
- Patients with renal replacement technique at the time of randomization
- Patients with some limitation of life support treatment (LLST)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Main objective is composed by: -Reduction of organ failure evaluated by Sepsis realted Organ failure Assessment score (SOFA scale) 72 h after administration of terlipressin / placebo. -Increase in ICU-free days of life measured 28 days after administration of terlipressin / placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock.
- Record updated
- 29 August 2024